MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Fatal evolution of cutaneous necrosis in a patient treated with subcutaneous apomorphine infusions

C. Marse, J. Benoit, F. Rocher, C. Giordana (Nice, France)

Meeting: 2019 International Congress

Abstract Number: 152

Keywords: Apomorphine, Parkinsonism

Session Information

Date: Monday, September 23, 2019

Session Title: Clinical Trials, Pharmacology and Treatment

Session Time: 1:45pm-3:15pm

Location: Agora 3 West, Level 3

Objective: Report a case of extensive cutaneous necrosis due to apomorphine treatment with fatal outcome.

Background: Subcutaneous (SC) apomorphine is used as a treatment of motor fluctuations in Parkinson’s disease (PD). However, severe cutaneous complications may restrain its use.

Method: Case report.

Results: A 79 years old patient suffering from PD for the past 12 years with major motor fluctuations and dyskinesias, occurring in daytime as well as at night, was treated with SC apomorphine via pump. The treatment was efficient on the patient’s motor symptoms despite the emergence, after one year of treatment, of a number of minor and self-resolving cutaneous lesions in regard of the injection sites. Progressive skin deterioration of the limbs, trunk and abdomen appeared after 4 years of continuous SC infusions, requiring hospitalization. At the patient’s arrival in our unit, the doses of apomorphine administered were 9mg/h from 8am to 8pm and 5mg/h from 8pm to 8am, with a total dose of 168mg/d. Apomorphine was withdrawn and levodopa/benserazide therapy was progressively increased up to 2000mg/day, in addition to his usual treatment by pramipexole 2.1 mg (base). Deep cleaning of the wounds and mechanical debridement of the lesions were performed without improvement. The ulcerations gradually worsened, and his general status deteriorated, with a considerable increase of the amount of time spent in an “off” state. Lacking alternative treatment, palliative care and support were initiated with fatal outcome within 1 month.

Conclusion: Nodules and indurations induced by SC apomorphine infusions are frequently described side effects whose pathophysiology still remains to be clearly elucidated . The occurrence of skin necrosis, a more serious but fortunately less common complication, should raise the question of pursuing or not the treatment. To our knowledge, this is the first case of progressive deterioration of a patient’s skin condition, with a particularly severe evolution which lead to fatal outcome.

To cite this abstract in AMA style:

C. Marse, J. Benoit, F. Rocher, C. Giordana. Fatal evolution of cutaneous necrosis in a patient treated with subcutaneous apomorphine infusions [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/fatal-evolution-of-cutaneous-necrosis-in-a-patient-treated-with-subcutaneous-apomorphine-infusions/. Accessed May 24, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/fatal-evolution-of-cutaneous-necrosis-in-a-patient-treated-with-subcutaneous-apomorphine-infusions/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley